ClinicalTrials.Veeva

Menu

Impact of Cancer Treatment on the Pelvic Floor Function in Survivors of Cervical Cancer

U

University of Sao Paulo

Status

Unknown

Conditions

Chemotherapy Effect
Pelvic Floor Disorders
Surgery
Radiotherapy; Complications
Cervical Cancer

Treatments

Other: Questionnaire application
Other: Assessment of the pelvic floor function

Study type

Observational

Funder types

Other

Identifiers

NCT03188744
5557/2017

Details and patient eligibility

About

Introduction: Pelvic floor muscle dysfunctions (PFMD) represent an important public health problem that manifests itself through lower urinary tract symptoms (LUTS), anorectal and sexual dysfunction. PFMD is a common problem in cervical cancer survivors (CC) with a negative impact on quality of life (QoL). Objective: This study aims to evaluate the effect of oncological treatment on the function of pelvic floor muscles (PFM) of survivors of CC. Methods: Patients diagnosed with CC, of any stage, histology and degree, accompanied by the Oncology Gynecology Service of the Hospital das Clínicas of the Medical School of Ribeirão Preto at the University of São Paulo, will be studied in the period between 2004 and 2014. Four study groups will be formed: (1) Patients with CC with PFMD; (2) Patients with CC without PFMD; : (3) Patients without CC with PFMD; (2) Patients without CC without PFMD. Non-cancer patients will be recruited into the community. For the analysis of the prevalence of PFMD will be applied to the discomfort Questionnaire on pelvic floor (IDPE-20) for evaluation of pelvic organ prolapse (POP) complaints, anorectal symptoms and urinary incontinence, and the Sexual Questionnaire for urinary incontinence and pelvic organ prolapse (PISQ -12) for evaluation of sexual function. Both questionnaires have already been validated for the Portuguese language and are specific for women with PFMD. The pelvic floor impact questionnaire (PFIQ-7) will also be applied to assess the impact of PFMD on quality of life, daily living activities and emotional health. For the evaluation of general QOL, the EORTC questionnaire QLQ-C30 and its specific module for patients with CC, QLQ-CX24 will be used. The evaluation of PFM function will include vaginal palpation (Modified Oxford Scale) and perineometry (Peritron).

Enrollment

150 estimated patients

Sex

Female

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Women diagnosed with CC; No distinction as to age, race, scholarity and religion; Women in follow-up at Clinical Hospital of Medical School of Ribeirão Preto of University São Paulo.

Exclusion criteria

  • Women who did not complete the proposed cancer treatment; Women who presented CC as the second malignant neoplasm; Pregnant women; Failure to respond to the proposed questionnaires.

Trial design

150 participants in 4 patient groups

Group 1
Description:
Patients with CC with PFMD.
Treatment:
Other: Questionnaire application
Other: Assessment of the pelvic floor function
Group 2
Description:
Patients with CC without PFMD.
Treatment:
Other: Questionnaire application
Other: Assessment of the pelvic floor function
Group 3
Description:
Patients without CC with PFMD.
Treatment:
Other: Questionnaire application
Other: Assessment of the pelvic floor function
Group 4
Description:
Patients without CC without PFMD.
Treatment:
Other: Questionnaire application
Other: Assessment of the pelvic floor function

Trial contacts and locations

1

Loading...

Central trial contact

Aline Ribeiro, MSc.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems